Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

5/28/25 7:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $AKRO alert in real time by email

SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 8:45 a.m. P.T.

A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.

About Akero Therapeutics

Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Akero's lead product candidate, efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 clinical studies: SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, and SYNCHRONY Real-World in patients with MASH or MASLD (metabolic dysfunction-associated steatotic liver disease). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and X for more information.

Investor Contact:

Christina Tartaglia

Precision AQ

332.322.7430

[email protected]

Media Contact:

Peg Rusconi

617.910.6217

[email protected]

Get the next $AKRO alert in real time by email

Recent Analyst Ratings for

$AKRO

Date	Price Target	Rating	Analyst
1/30/2025	$35.00 → $63.00	Neutral → Buy	BofA Securities
1/27/2025	$50.00 → $72.00	Buy	H.C. Wainwright
11/18/2024	$65.00	Buy	Citigroup
4/22/2024	$30.00	Neutral	BofA Securities
9/19/2023	$69.00	Overweight	Cantor Fitzgerald
8/28/2023	$83.00	Buy	UBS
1/27/2023	$40.00 → $65.00	Equal-Weight → Overweight	Morgan Stanley
9/14/2022	$10.00 → $50.00	In-line → Outperform	Evercore ISI

More analyst ratings

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

Chat with this insight

Recent Analyst Ratings for $AKRO

$AKRO Press Releases

Fastest customizable press release news feed in the world

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

$AKRO Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Graham G. Walmsley bought $8,787,921 worth of shares (200,000 units at $43.94) (SEC Form 4)

Director Graham G. Walmsley bought $9,600,000 worth of shares (200,000 units at $48.00) (SEC Form 4)

Graham G. Walmsley bought $1,982,940 worth of shares (100,000 units at $19.83) (SEC Form 4)

$AKRO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Senior VP, Commercial Strategy Lamy Patrick exercised 4,000 shares at a strike of $44.37 and sold $200,000 worth of shares (4,000 units at $50.00) (SEC Form 4)

Chief Development Officer Yale Catriona exercised 10,000 shares at a strike of $21.10 and sold $392,978 worth of shares (10,000 units at $39.30) (SEC Form 4)

President and CEO Cheng Andrew sold $1,244,455 worth of shares (30,000 units at $41.48), decreasing direct ownership by 5% to 594,324 units (SEC Form 4)

$AKRO Financials

Live finance-specific insights

Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

$AKRO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Akero Therapeutics upgraded by BofA Securities with a new price target

H.C. Wainwright reiterated coverage on Akero Therapeutics with a new price target

Citigroup initiated coverage on Akero Therapeutics with a new price target

$AKRO SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Akero Therapeutics Inc.

Amendment: SEC Form SCHEDULE 13G/A filed by Akero Therapeutics Inc.

SEC Form 144 filed by Akero Therapeutics Inc.

$AKRO Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Akero Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Akero Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Akero Therapeutics Inc.

$AKRO Leadership Updates

Live Leadership Updates

Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy

Recent Analyst Ratings for
$AKRO

$AKRO
Press Releases

$AKRO
Insider Purchases

$AKRO
Insider Trading

$AKRO
Financials

$AKRO
Analyst Ratings

$AKRO
SEC Filings

$AKRO
Large Ownership Changes

$AKRO
Leadership Updates